FDA Recommends Pre-BLA Meeting for Ersodetug in Congenital HI Despite Primary Endpoint Miss
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute announced that the FDA recommended a Type B pre-BLA meeting for its drug candidate ersodetug in congenital hyperinsulinism, despite the Phase 3 sunRIZE study missing its primary endpoint.
Key Events · Product Development and Regulatory · RZLT
-
FDA Recommends Pre-BLA Meeting
The U.S. Food and Drug Administration (FDA) recommended a Type B pre-Biologics License Application (BLA) meeting for ersodetug in congenital hyperinsulinism (HI) following a preliminary review of data from the Phase 3 sunRIZE study.
-
sunRIZE Trial Missed Primary Endpoint
The Phase 3 sunRIZE study did not meet its primary endpoint, as reductions in hypoglycemia events were not statistically significant compared to placebo. However, consistent and clinically relevant improvements were observed in other continuous glucose monitoring (CGM) based endpoints.
-
FDA Cautions on Approvals
The FDA explicitly did not opine on the approvability of ersodetug and noted that any determination would be made during a formal BLA review. The agency also stated that additional clinical data, potentially including a new randomized controlled trial, might be required for approval.
-
Future BLA Strategy Under Review
Rezolute will evaluate its overall BLA submission strategy for both congenital HI and tumor HI (upLIFT study, with topline results expected this quarter) after the upLIFT study results are announced.
Analysis · RZLT · Life Sciences
The FDA's recommendation for a pre-BLA meeting for ersodetug in congenital hyperinsulinism is a significant development, especially given that the Phase 3 sunRIZE study did not meet its primary endpoint. While the trial showed clinically relevant improvements in other measures, the primary endpoint miss is a concern. However, the FDA's willingness to engage in pre-BLA discussions, acknowledging the challenges in this patient population and the unmet need, suggests a potential path forward. The company will now evaluate its overall BLA submission strategy, including the upcoming upLIFT study results for tumor HI. Investors should note the FDA explicitly did not opine on approvability and warned that additional clinical data, potentially including a new trial, might be required.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 32.4% of the 2200 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RZLT was trading at $4.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $387.9M. The 52-week trading range was $1.07 to $11.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.